2007
DOI: 10.1016/j.ijrobp.2007.07.150
|View full text |Cite
|
Sign up to set email alerts
|

High Dose Rate Brachytherapy (HDR-BT) as Monotherapy for Favorable Prostate Cancer: Excellent 5-Year Control Rates and Low Toxicity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0
1

Year Published

2008
2008
2013
2013

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(13 citation statements)
references
References 0 publications
0
12
0
1
Order By: Relevance
“…Thus, although the number of hospital visits is lower than with EBRT, they are more intense and require inpatient stay. While the results are not as mature as with HDR boost, monotherapy studies have reported freedom from biochemical relapse rates of 89-100% in low-and intermediate-risk patients, which compare favourably with findings with LDR brachytherapy [70][71][72][73][74][75][76]. At present this approach is not recommended routinely, but should the long-term outcome data become favourable, this will undoubtedly help to establish HDR monotherapy as a credible option for localised prostate patients.…”
Section: Future Directions For High Dose Rate Prostate Brachytherapymentioning
confidence: 87%
“…Thus, although the number of hospital visits is lower than with EBRT, they are more intense and require inpatient stay. While the results are not as mature as with HDR boost, monotherapy studies have reported freedom from biochemical relapse rates of 89-100% in low-and intermediate-risk patients, which compare favourably with findings with LDR brachytherapy [70][71][72][73][74][75][76]. At present this approach is not recommended routinely, but should the long-term outcome data become favourable, this will undoubtedly help to establish HDR monotherapy as a credible option for localised prostate patients.…”
Section: Future Directions For High Dose Rate Prostate Brachytherapymentioning
confidence: 87%
“…It may also be administered as the sole treatment for low risk and some intermediate risk patients (35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47). There is a separate ACR-ASTRO Practice Guideline for Transperineal Permanent Brachytherapy of Prostate Cancer (48).…”
Section: Prostatementioning
confidence: 99%
“…Although ample reports have described results of lengthy follow-up when HDR brachytherapy was combined with external-beam RT, 3,13-23 follow-up duration among patients treated with HDR brachytherapy alone has been shorter. 11,[24][25][26][27][28][29] This follow-up duration contrasts with the longer observation periods available in the literature for patients treated with LDR brachytherapy alone. 5…”
Section: Advantages Of Hdr Brachytherapymentioning
confidence: 99%
“…In performing HDR brachytherapy alone, 1 or 2 implantation sessions have been used to deliver 4 or 6 doses of 600 cGy to 950 cGy each, for a total dose of 3800 cGy to 5400 cGy. 11,[24][25][26][27][28][29] This approach has provided excellent intermediate-term results regarding freedom from biochemical relapse for certain groups of patients with prostate cancer (Table 6) These outcomes appear to compare favorably with results of permanent LDR brachytherapy 5,11,25 and with results of the combination of HDR brachytherapy and external-beam RT. 40,41 Nevertheless, the reported patient followup duration after HDR brachytherapy alone has been shorter than that available for patients treated with combined HDR brachytherapy and external-beam RT.…”
Section: Hdr Brachytherapy Alonementioning
confidence: 99%
See 1 more Smart Citation